Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01457391 · ClinicalTrials.gov registry record · Phase 3
Cognitive Behavioral Therapy (CBT) for Posttraumatic Stress Disorder (PTSD) in Community Addiction Treatment
A Phase 3 study of Stress Disorders, Post-Traumatic and Substance-Related Disorders, sponsored by Dartmouth-Hitchcock Medical Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 443
- Enrollment target
- 4
- Study locations
NCT01457391: Completed Phase 3 study of Stress Disorders, Post-Traumatic and Substance-Related Disorders, sponsored by Dartmouth-Hitchcock Medical Center.
NCT01457391 is a Phase 3 study of Stress Disorders, Post-Traumatic and Substance-Related Disorders that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 443 participants, above the 149-participant average among 66 other Stress Disorders, Post-Traumatic trials with a reported enrollment target (197% higher). The trial reports 4 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01457391, a Phase 3 study of Stress Disorders, Post-Traumatic and Substance-Related Disorders, has completed, sponsored by Dartmouth-Hitchcock Medical Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 443 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this phase of the study is to assess the efficacy of CBT for PTSD, as delivered by routine addiction counselors in community treatment programs, and to compare CBT for PTSD with both Individual Addiction Counseling (IAC) and Treatment as Usual (TAU) on the primary outcomes.
Conditions Studied
Interventions
- BEHAVIORAL Cognitive Behavioral Therapy
- BEHAVIORAL Treatment-as-usual
- BEHAVIORAL Individual Addiction Counseling
Study Locations (4)
Vermont
- Central Vermont Substance Abuse Services - Berlin Corners
- Brattleboro Retreat - Brattleboro
- Howard Center - Burlington
- Evergreen - Rutland Mental Health - Rutland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 443 participants |
| Start Date | 2010-12 |
| Est. Completion | 2014-04 |
| Phase | Phase 3 |
What the finished NCT01457391 record still lists
NCT01457391 is an interventional study that assigns participants to a tested intervention. The registered 443 participants enrollment target is mid-sized for trials with a published cap, above the 149-participant average among 66 other Stress Disorders, Post-Traumatic trials with a reported enrollment target (197% higher).
The record links to 2 conditions, with Stress Disorders, Post-Traumatic appearing as the primary indexed condition, and to 3 interventions - of which Cognitive Behavioral Therapy is the first listed.
NCT01457391 reports a single indexed study location in Vermont.
Frequently Asked Questions
What is clinical trial NCT01457391 about?
NCT01457391 is a clinical study titled "Cognitive Behavioral Therapy (CBT) for Posttraumatic Stress Disorder (PTSD) in Community Addiction Treatment". The purpose of this phase of the study is to assess the efficacy of CBT for PTSD, as delivered by routine addiction counselors in community treatment programs, and to compare CBT for PTSD with both Individual Addiction Counseling (IAC) and Treatment as Usual (TAU) on the primary outcomes.
What is the current status of trial NCT01457391?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 443 participants. The study started on 2010-12. Estimated completion is 2014-04.
What conditions does trial NCT01457391 study?
This clinical trial studies the following conditions: Stress Disorders, Post-Traumatic, Substance-Related Disorders.
What interventions are being tested in trial NCT01457391?
The interventions under investigation include: Cognitive Behavioral Therapy (BEHAVIORAL), Treatment-as-usual (BEHAVIORAL), Individual Addiction Counseling (BEHAVIORAL).
Who is sponsoring clinical trial NCT01457391?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01457391 being conducted?
This trial has 4 study locations across Vermont. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stress Disorders, Post-Traumatic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01457391's enrollment target sits among peer trials
443 5th of 66 higher than 62 of 66 other Stress Disorders, Post-Traumatic trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stress Disorders, Post-Traumatic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Prazosin for Treatment of Patients With Alcohol Dependence (AD) and Post Traumatic Stress Disorder (PTSD).
COMPLETED · Phase 3
-
Fluoxetine vs EMDR to Treat Post-Traumatic Stress Disorder (PTSD)
COMPLETED · Phase 3
-
Manage Emotions to Reduce Aggression (MERA)
RECRUITING · NA
-
SMART Therapist Training: A Hybrid Factorial-SMART Design
RECRUITING · NA
-
Overcontrol and Suicide in PTSD
RECRUITING
-
Postpartum Care in the NICU (PeliCaN) Transitions
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06780670 · 443 participants · Phase 2
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
- NCT06348394 · 444 participants · NA
Intracardiac Versus Transesophageal Echocardiographic Guidance for Left Atrial Appendage Occlusion
- NCT06700343 · 444 participants · Phase 3
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
- NCT03704766 · 442 participants · NA
Alpha-Defensin and Synovial Proteins to Improve Detection of Pediatric Septic Arthritis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia